nik-macmillan-280300.jpg

investors

 
 

STOCK INFORMATION

BlissCo is currently trading on the following stock exchanges:

Canadian Stock Exchange (CSE) as BlissCo Cannabis Corp. (BLIS)

Frankfurt Stock Exchange (FRA) as GQ4B:GR

 

BlissCo Ecosystem Secures Support from CEO of TallGrass as Advisor to Multi-Billion Dollar Cannabis Wellness Market

  • Canadian medical cannabis market expected to grow to $8.7 billion in the first year of legalization

Not for distribution in the U.S. or to U.S. newswire services.

Vancouver, British Columbia – July 3, 2018 – BlissCo Cannabis Corp. (FRA: GQ4B) (CSE: BLIS), (“BlissCo”) is pleased to announce the appointment of Matt Breech, CEO of TallGrass, to the company’s advisory board.

"Mr. Breech brings decades of success within both the hemp and regulated health supplement industry. He has tremendous experience in developing and building distribution channels for health products nationwide. We believe that Matt will add tremendous value and help BlissCo to achieve its growth goals.” said Damian Kettlewell, CEO of BlissCo Cannabis Corp.

Mr. Breech co-founded TallGrass over 20 years ago in 1994. The company originally sold hemp t-shirts and has since evolved its own ecosystem into selling natural supplements, superfoods and other health and wellness products including products under the Botanica brand. The company distributes to 1,000 wellness stores across Canada.

“I have a lot of experience working with Health Canada in terms of regulatory and licensing specifically for natural health products. It is a unique challenge because before you’re allowed to take these products to market, the products must comply with a pre-authorized marketing system, and I have a ton of experience navigating strict regulation,” said Matt Breech. “We also have an importer license for every product that we sell and I have a lot of familiarity with that process. This is another area where I am able to support Damian in the further development of BlissCo’s global cannabis ecosystem.

Statista reported that the Canadian market value of medical cannabis in 2017 was estimated at $4.9-$8.7 billion. Post-legalization, the market is expected to grow to $8.7 billion in its first year, with an ancillary market bringing an estimated $22.6 billion.

“BlissCo is a part of a thriving sector that is just emerging, and there is already a ton of interest. What really sets BlissCo apart is that the company has a lot of integrity, it doesn’t surprise me at all that the company is welcoming such great entities into its ecosystem. BlissCo is in operation for the right reasons,” said Breech.

 

On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

 

For further information please contact:

Ariel Jack Lewinski, Business Development & Investor Relations 

 1-604-377-7533

ariel.lewinski@blissco.com

 

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

See All Investor Updates

OUR COMPANY

As Canada is primed as a global leader and first mover in the cannabis industry, BlissCo is uniquely poised in the rapidly growing multi-billion dollar market and in various international markets as cannabis regulations progress.

BlissCo, founded in 2013, is a Canadian vertically integrated cultivation, extraction and distribution focused cannabis brand that earned its Access to Cannabis for Medical Purposes Regulations (ACMPR) license to cultivate from Health Canada on March 29, 2018.

BlissCo's state-of-the-art production facility, located in Metro Vancouver, is purposefully designed as a hub for research, cultivation, processing, extraction, packaging and distribution.

Now with the ACMPR license to cultivate, BlissCo will commence its operation to harvest premium cannabis within its' urban facility in Metro Vancouver.  BlissCo also has a multi-year supply agreement in place with a Canadian Licensed Producer of characteristically sun-grown premium medicinal cannabis to purchase supply in large volumes (news release). This premium bulk cannabis will be brought to our secure and pristine facility in British Columbia for processing and then be packaged for sale and distribution to our growing patient list when BlissCo has appropriately received its license for sale. 

BlissCo was founded with the assistance of a team of advisors, including medical and naturopathic doctors, has intentionally engaged with the medical community to understand how to contribute to improved patient health with medicinal cannabis products. A large part of our strategy for growth centres on how to securely integrate and collaborate with the healthcare system.

The BlissCo team has deep domain expertise in the critical category success areas:

  • Multi-province controlled substance distribution (BC and Alberta)
  • Cultivation and product safety, consistency and security
  • Indoor cultivation, controlled environments ensuring high standards &  consistent products.
  • Quality assurance, product safety, 3rd Party GMP Audits & Certifications.

Milestones

2018

February

Strategic partnership with the Supreme Cannabis Company

Trading on Canadian Securities Exchange (CSE:BLIS)

March
ACMPR License to Produce earned

May

Cannabis plant starting material to arrive at BlissCo's facility and growing commences. 

ACMPR Cannabis Oil Extraction License application submitted

June

Sign agreement to export 720 kilograms of medical cannabis to Germany

July

ACMPR License to Sell application submitted

Sign supply agreement with GreenSeal Cannabis

Sign e-commerce and technology service agreement with Namaste Technologies (TSXV: N) 

2017

February
Confirmation of Readiness for Inspection received from Health Canada

May
Confirmation of Readiness for License from Health Canada

August
Close on purchasing facility for $2.4m

September
Earn Building Permit from Township of Langley
Commence Construction

2014

July
ACMPR Licensed Submitted

 


Downloads and Links

BlissCo Cannabis Corp. CSE listing

BlissCo Cannabis Corp. Sedar filing information.

BlissCo logo

To learn more about investment opportunities please contact investors@blissco.com.